Coverage appeal AI
Claimable
Claimable is a paid patient-facing service that generates evidence-backed appeals for denied medications, currently covering over 85 treatments in condition areas like migraine, rheumatology, GLP-1s, asthma, and PANS/PANDAS, at a flat $39.95 plus shipping unless a sponsor covers the cost. It is strongly action-oriented for patients, and its 80 percent success-rate claim is vendor-reported rather than independently verified. CAIHL review should watch the growing pharma and health-system sponsorship layer, which funds free appeals but also turns appeal and denial data into market-access intelligence.
Public-source research has been drafted; final human publication review and change-log detail are still required.
Summary judgment · 72% toward patient-directed
Potentially agency-expanding, with sponsorship-alignment caveat
Claimable arms patients with evidence-backed appeals against payer denials, but its no-cost appeals and April 2026 enterprise platform are funded by pharma manufacturers and health systems whose interest is keeping patients on specific therapies.
Patient agency
How this tool changes agency
The whole service is appeal action: evidence-matched letters, fax and mail delivery to payer decision-makers and regulators, urgent review requests, reminders, and guidance on second-level appeals, external review, and regulatory escalation when appeals fail.
Use is voluntary and patient-initiated, but a $39.95 flat fee plus shipping applies unless a sponsor qualifies the patient, and only about 85 supported treatments in selected condition areas are eligible.
Patient-facing signals
Who does this AI serve?
The consumer product serves patients fighting denials, but no-cost appeals are funded by support partners, and an enterprise platform sells appeal automation and denial analytics to pharma manufacturers and health systems whose interest is therapy continuation.
Can patients tell AI is involved?
AI-powered appeal drafting is openly marketed, and the vendor states that sponsored no-cost programs are disclosed to patients during consent.
Can patients meaningfully choose?
Use is voluntary and patient-initiated, but a $39.95 flat fee plus shipping applies unless a sponsor qualifies the patient, and only about 85 supported treatments in selected condition areas are eligible.
Can patients correct or challenge what the AI produces?
The vendor describes a human-in-the-loop flow where patients review, edit, and approve every appeal before submission, plus deletion and access-revocation rights, but these workflows were not verified in-app.
Does it help patients understand or act?
The whole service is appeal action: evidence-matched letters, fax and mail delivery to payer decision-makers and regulators, urgent review requests, reminders, and guidance on second-level appeals, external review, and regulatory escalation when appeals fail.
Text findings
Who is left out or burdened?
Cost, condition coverage, and access limits
Patients outside the roughly 85 supported medications are excluded, the $39.95 fee burdens unsponsored patients despite a nonprofit Coverage Fund referral, and language, disability, and non-digital access support are not documented.
What happens to patient data?
Meaningful disclosure, with partner-sharing caveats
Vendor claims HIPAA-compliant AWS hosting with BAAs, HIPAA certification via Workstreet, SOC 2 in progress, encryption, and deletion rights, and says it does not sell personal data, but aggregated denial analytics feed pharma-facing strategic intelligence and the privacy policy permits sharing with licensors or partners for analysis or marketing subject to consent.
Are the clinical boundaries clear?
Mostly clear
Claimable drafts coverage appeals around an existing clinician prescription and does not present itself as medical or legal advice, with human review described for AI outputs, though boundary language is spread across FAQ and partner pages rather than a single patient-facing statement.
Who defined what good looks like?
Vendor-defined
The 80 percent success rate and 10-day resolution figures are self-reported marketing claims, with substantial press coverage including Bloomberg and TIME recognition but no independent audit or peer-reviewed evaluation found in this pass.
Review method
Public-source review of the official homepage and FAQ, about page, for-pharma partner page, and privacy policy, plus the April 2026 enterprise launch press release and credible news coverage confirmed via search; no product walkthrough, vendor interview, or independent verification of success-rate claims.
Draft profile · Medium draft, official sources and press coverage